Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A mixed methods evaluation of a shared electronic health record between general practice and community pharmacy.

International journal of clinical pharmacy·2025

Same author

Diet outperforms microbial transplant to drive microbiome recovery in mice.

Nature·2025

Same author

A Small Device May Deliver King-Sized Solutions for Patients With an Exacerbation of Cystic Fibrosis.

International journal of pediatrics·2024

Same author

'Flashforward' mental imagery in adolescents: exploring developmental differences and associations with mental health.

Behavioural and cognitive psychotherapy·2024

Same author

Specificity of Episodic Future Thinking in Adolescents: Comparing Childhood Maltreatment, Autism Spectrum, and Typical Development.

Research on child and adolescent psychopathology·2024

Same author

Awareness of social care needs in people with epilepsy and intellectual disability.

Epilepsy & behavior : E&B·2023

Search research articles

Related Experiment Video

Updated: May 8, 2026

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

Photodynamic therapy effectively palliates gynecologic malignancies.

H Godoy¹, P Vaddadi, M Cooper

¹Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.

European Journal of Gynaecological Oncology

|September 12, 2013

Summary

Photodynamic therapy (PDT) using Photofrin II offers an effective treatment for recurrent gynecologic cancers. This laser-based therapy shows promise for complete response in select patients, particularly those with superficial lesions.

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Related Experiment Videos

Last Updated: May 8, 2026

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Area of Science:

Oncology
Photomedicine

Background:

Recurrent gynecologic malignancies present a significant challenge, necessitating novel therapeutic approaches.
Photodynamic therapy (PDT) is an emerging treatment modality utilizing photosensitizers and light activation.

Purpose of the Study:

To evaluate the efficacy and safety of photodynamic therapy (PDT) with Photofrin II for patients with recurrent gynecologic malignancies.
To assess response rates and toxicity in a cohort of patients with various gynecologic cancer recurrences.

Main Methods:

Patients received intravenous Photofrin II (2 mg/kg), followed by tumor exposure to 630 nm red laser light.
Treatment involved flexible quartz fiber delivery of laser light for uniform tumor illumination.

Main Results:

Thirty-two patients with recurrent gynecologic malignancies underwent 45 PDT treatments.
Complete response was observed in 82% of patients with metastatic cutaneous lesions and 24% with vaginal, cervical, or anal recurrences.
Treatment toxicity was limited to localized burning, pain, and edema; no treatment-related deaths occurred.

Conclusions:

Photodynamic therapy (PDT) is an effective alternative for recurrent gynecologic malignancies, especially when conventional options are limited.
PDT offers potential for complete response and palliation in patients with superficial recurrent lesions, particularly in the absence of distant metastases.